Morgan Stanley upgraded UCB to Equal Weight from Underweight with a price target of EUR 105, up from EUR 75. The analyst cites stronger than expected launch trends for Bimzelx to treat psoriasis for the upgrade.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UCBJF: